Corrigendum to “Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9” [Stem Cell Res. 56 (2021) 102554]
Ivan Pavlinov,
Atena Farkhondeh,
Shu Yang,
Miao Xu,
Yu-Shan Cheng,
Jeanette Beers,
Jizhong Zou,
Chengyu Liu,
Matthew Might,
Steven Rodems,
Karsten Baumgärtel,
Wei Zheng
Affiliations
Ivan Pavlinov
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
Atena Farkhondeh
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
Shu Yang
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
Miao Xu
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
Yu-Shan Cheng
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
Jeanette Beers
iPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Jizhong Zou
iPSC Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Chengyu Liu
Transgenic Core, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Matthew Might
University of Alabama at Birmingham, Birmingham, AL, USA
Steven Rodems
Travere Therapeutics, 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA
Karsten Baumgärtel
Travere Therapeutics, 3611 Valley Centre Drive, Suite 300, San Diego, CA, USA
Wei Zheng
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA; Corresponding author
